Do not use in animals with known hypersensitivity to fluoroquinolones or to any of the excipients. To limit development of resistance, do not use fluoroquinolones as prophylaxis or metaphylaxis to prevent diarrhoea at weaning.
Do not use in cases where the pathogen involved is resistant to other fluoroquinolones (cross resistance).
Special precautions for use in animals
Official and local antimicrobial policies should be taken into account when this product is used. Fluoroquinolones should be reserved for the treatment of clinical conditions which have responded poorly, or are expected to respond poorly, to other classes of antimicrobials. Wherever possible, use of the product should only be based on susceptibility testing. Use of the product deviating from the instructions given in the SPC may increase the prevalence of bacteria resistant to the fluoroquinolones and may decrease the effectiveness of treatment with other quinolones due to the potential for cross resistance.
Special precautions to be taken by the person administering the veterinary medicinal product to animals
People with known hypersensitivity to (fluoro)quinolones and benzyl alcohol should avoid any contact with the product. Wash hands after use. Avoid contact of the skin and eyes with the product. If the product comes into contact with the skin or eyes, rinse with copious amounts of water. Care should be taken to avoid accidental self-injection. In the event of accidental self-administration, the user should immediately seek professional medical care. Accidental self-injection can induce a slight irritation.
Adverse reactions (frequency and seriousness)
Local reactions can be observed at the injection site, which disappear within 36 days.
Pain at the injection site has been commonly reported (more than 1 but less than 10 animals in 100 animals).
Use during pregnancy, lactation or lay
Laboratory studies in rats and rabbits have not produced any evidence of a teratogenic, embryotoxic or maternotoxic effect associated with the use of marbofloxacin. The safety of the veterinary medicinal product has not been established at 8 mg/kg in pregnant sows or in suckling piglets when used in sows. Use only according to the benefit/risk assessment carried out by the responsible veterinarian.
Interaction with other medicinal products and other forms of interaction
Overdose (symptoms), emergency procedures, antidotes), if necessary
Lesions of the joint cartilage, potentially leading to difficulties in movement, were observed in some animals treated at three times the recommended dose and treatment duration.
Meat and offal: 9 days
In the absence of compatibility studies, this veterinary medicinal product must not be mixed with other veterinary medicinal products.